Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tadalafil (Adcirca®) cannot be endorsed for use within NHS Wales for the treatment of pulmonary arterial hypertension (PAH) |
||
|
||
Medicine details |
||
| Medicine name | tadalafil (Adcirca®) | |
| Formulation | 20 mg film-coated tablet | |
| Reference number | 296 | |
| Indication | For the treatment of pulmonary arterial hypertension (PAH). |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Cardiovascular system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 26/04/2010 | |